Study compares standard against newer treatment in women whose breast cancer has spread

Results show interesting trend in overall survival

2012-12-07

(Press-News.org) (Lebanon, NH, 12/7/12) — Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival. This study was presented today by Peter A. Kaufman, M.D., during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.

"We didn't show a statistically significant superiority of eribulin over capecitabine, which was our goal," said Peter A. Kaufman, MD, associate professor of medicine at the Geisel School of Medicine at Dartmouth, and oncologist at Dartmouth-Hitchcock and Norris Cotton Cancer Center in Lebanon, N.H. "However, eribulin demonstrated a trend favoring an overall survival benefit, in comparison to capecitabine, which is a widely accepted and used standard therapy in this setting. Additionally, this is the first study demonstrating that eribulin is active earlier in the course of metastatic breast cancer," Kaufman said.

In 2010, the FDA approved eribulin for the treatment of patients with metastatic breast cancer who had previously received an anthracycline and a taxane and at least two cytotoxic chemotherapy treatment regimens for metastatic breast cancer. The FDA granted approval based on data showing a statistically significant improvement in overall survival compared with current treatments.

Kaufman and colleagues examined whether eribulin would be effective as an earlier-line treatment in women with metastatic breast cancer. They randomly assigned 1,102 patients to eribulin or capecitabine. Patients had all received prior anthracycline- and taxane-based therapy and received the study drug as the first, second or third line of therapy for metastatic disease.

The median overall survival for patients treated with eribulin was 15.9 months compared with 14.5 months for patients treated with capecitabine.

"Although we did not meet our primary endpoints, this is still the first study demonstrating the activity of eribulin in earlier lines of treatment of metastatic breast cancer," Kaufman said. "Eribulin is an active therapy in this setting, and overall, it has potentially comparable activity to capecitabine, which is a widely used treatment in this patient population."

As a next step researchers are evaluating how eribulin performed among subsets of women in the study who share similar traits. Exploratory analyses of patient subsets showed that the median overall survival in women with HER2-negative breast cancer was 15.9 months with eribulin compared with 13.5 months with capecitabine. In women with triple-negative breast cancer, which is a particularly aggressive subset, the median overall survival was 14.4 months with eribulin compared with 9.4 months with capecitabine.

Kaufman and colleagues are still compiling data from the quality-of-life analysis, which according to Kaufman, will help guide their next steps in further studying eribulin in this patient population.

### About Norris Cotton Cancer Center at Dartmouth-Hitchcock: Norris Cotton Cancer Center combines advanced cancer research at Dartmouth College and the Geisel School of Medicine at Dartmouth with patient-centered cancer care provided at Dartmouth-Hitchcock Medical Center, at Dartmouth-Hitchcock regional locations in Manchester, Nashua, and Keene, NH, and St. Johnsbury, VT, and at 12 partner hospitals throughout New Hampshire and Vermont. It is one of 41 centers nationwide to earn the National Cancer Institute's "Comprehensive Cancer Center" designation. Learn more about Norris Cotton Cancer Center research, programs, and clinical trials online at cancer.dartmouth.edu.

ELSE PRESS RELEASES FROM THIS DATE:

The effect of treating institution on outcomes in head and neck cancer

2012-12-07

Alexandria, VA — Patients with head and neck cancer receiving radiation treatment at an academic center have a higher survival rate than those receiving treatment at a community center, according to a study in the December 2012 issue of Otolaryngology–Head and Neck Surgery. "Despite similar rates of treatment completion and rate of treatment breaks between groups, patients treated in academic centers had more advanced cancer but better survival," the authors state in their conclusion. The study evaluated differences in patient characteristics, treatment, and cancer ...

Point of light

2012-12-07

PASADENA, Calif.—As technology advances, it tends to shrink. From cell phones to laptops—powered by increasingly faster and tinier processors—everything is getting thinner and sleeker. And now light beams are getting smaller, too. Engineers at the California Institute of Technology (Caltech) have created a device that can focus light into a point just a few nanometers (billionths of a meter) across—an achievement they say may lead to next-generation applications in computing, communications, and imaging. Because light can carry greater amounts of data more efficiently ...

How the common 'cat parasite' gets into the brain

2012-12-07

"We believe that this knowledge may be important for the further understanding of complex interactions in some major public health issues, that modern science still hasn't been able to explain fully", says Antonio Barragan, researcher at the Center for Infectious Medicine at Karolinska Institutet and the Swedish Institute for Communicable Disease Control. "At the same time, it's important to emphasize that humans have lived with this parasite for many millennia, so today's carriers of Toxoplasma need not be particularly worried". The current study, which is published ...

Putting electronic cigarettes to the test

2012-12-07

Electronic cigarettes are experiencing somewhat of a boom at the moment. An estimated two million people in Germany have already turned to the vapor cigarette, which many view as a healthy alternative to conventional smoking. However, a number of voices, primarily from the political sphere, are warning of possible health risks, claiming that the long-term consequences cannot yet be foreseen. Studies to date have come to mixed conclusions. There is a general lack of substantiated facts, fuelling an ongoing battle between supporters and opponents. By carrying out a new, independent ...

Group interaction among elderly is the key to significant health outcomes

2012-12-07

The health benefits of 'water clubs' in care homes for the elderly, where residents gather together regularly to drink water , owe as least as much to the social nature of the activity as to the value of drinking water itself, an investigation by psychologists has shown. The study, funded by the Economic and Social Research Council (ESRC), supports other findings that interventions aimed at improving individuals' wellbeing and quality of life can be far more effective if they are carried out among groups of people in ways that generate a strong sense of group identity. A ...

X-ray vision can reveal the moment of birth of violent supernovae

2012-12-07

A team of astronomers led by the University of Leicester has uncovered new evidence that suggests that X-ray detectors in space could be the first to witness new supernovae that signal the death of massive stars. Astronomers have measured an excess of X-ray radiation in the first few minutes of collapsing massive stars, which may be the signature of the supernova shock wave first escaping from the star. The findings have come as a surprise to Dr Rhaana Starling, of the University of Leicester Department of Physics and Astronomy whose research is published in the ...

Winning the battle against leukaemia: Positive early results in clinical trial for DNA vaccine

2012-12-07

Early results of a trial to treat leukaemia with a WT1 DNA vaccine, has shown robust vaccine-specific antibody responses in all vaccinated patients evaluated to date. Furthermore, T cell immune responses, including those of the "killer T cells," were detected. Antibody and T cell responses are strong signals of the DNA vaccine's potential to treat the disease. Presented at the DNA Vaccines 2012 conference in California by Christian Ottensmeier, the trial's principal investigator and Professor of Experimental Cancer Research at the University of Southampton, these interim ...

Rilpivirine for HIV: Added benefit for single agent proven

2012-12-07

Since the start of 2012, a new drug called rilpivirine has been available for adult patients infected with the human immunodeficiency virus type 1 (HIV-1). It is marketed by two different pharmaceutical companies, by one as a single agent (trade name Edurant®) and by the other as a fixed combination with other HIV drugs (trade name Eviplera®). In two early benefit assessments pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the Institute for Quality and Efficiency in Health Care (IQWiG) has investigated whether the two new drugs have advantages ...

High hormone levels put young black males at risk for cardiovascular disease

2012-12-07

AUGUSTA, Ga. – Increased levels of the hormone aldosterone in young black males correlate with an unhealthy chain of events that starts with retaining too much salt and results in an enlarged heart muscle, researchers say. The findings indicate physicians may want to reach for aldosterone inhibitors early in their effort to control blood pressure and reduce cardiovascular risk in young black males. Their studies of a cohort of 191 healthy black and white 15- to 19-year-olds showed that only in the black males was higher aldosterone associated with impaired sodium excretion, ...

A pattern given by nature

2012-12-07

A new plant-parasitic nematode worm (Meloidoderita salina) was found in a tidal salt marsh at Mont Saint Michel Bay (MSMB) in France, where its abbey is a world-famous historical heritage. The species name 'salina' refers to salty soil and is derived from the Latin word 'sal' or 'salis' meaning 'salt'. The study was published in the peer-reviewed, open source scientific journal ZooKeys. The female nematode worm of Meloidoderita salina deposits its eggs in two different structures. One of them is called egg mass which is an external gelatinous matrix, the other one is ...

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Study compares standard against newer treatment in women whose breast cancer has spread

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: